Beneficial effect of short-term exposure of human NK cells to IL15/IL12 and IL15/IL18 on cell apoptosis and function

Cellular Immunology

Volumn 234, Issue 1, 2005, Pages 67-75

  Sotiriadou, Nectaria N ^a   Perez, Sonia A ^a   Gritzapis, Angelos D ^a   Mahaira, Louisa G ^a   Salagianni, Maria ^a   Baxevanis, Constantin N ^a   Papamichail, Michael ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

ADCC; Apoptosis; Cancer immunotherapy; CD16; CD56; Cytotoxicity; IL12; IL15; IL18

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; FC RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18 BINDING PROTEIN; MONOKINE;

APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL CULTURE; CELL CYCLE; CELL FUNCTION; CELL LINE; CYTOKINE PRODUCTION; CYTOTOXICITY; HUMAN; HUMAN CELL; INCUBATION TIME; PRIORITY JOURNAL;

ANTIGENS, CD56; APOPTOSIS; CELL LINE, TUMOR; CHEMOKINES; HUMANS; INTERLEUKIN-12; INTERLEUKIN-15; INTERLEUKIN-18; KILLER CELLS, NATURAL; KINETICS; RECEPTORS, IGG; TIME FACTORS;

EID: 23744458017     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellimm.2005.05.002     Document Type: Article

References (32)

1. A. Cerwenka, and L.L. Lanier Natural killer cells, viruses and cancer Nat. Rev. Immunol. 1 2001 41 49
2. M.A. Caligiuri, A. Zmuidzinas, T.J. Manley, H. Levine, K.A. Smith, and J. Ritz Functional consequences of interleukin-2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors J. Exp. Med. 171 1990 1509 1526
3. B. Naume, A.C. Johnsen, T. Espevik, and A. Sundan Gene expression and secretion of cytokines and cytokine receptors from highly purified CD56+ natural killer cells stimulated with interleukin-2, interleukin-7 and interleukin-12 Eur. J. Immunol. 23 1993 1831 1838
4. J. Parrish-Noval, D.C. Foster, R.D. Holly, and C.H. Clegg Interleukin-21 and IL-21 receptor: novel effectors of NK and T cell responses J. Leukoc. Biol. 72 2002 856 893
5. J. Dunne, S. Lynch, C. O' Farrelly, S. Todryk, J.E. Hegarty, C. Feighery, and D.G. Doherty Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL15 J. Immunol. 167 2001 3129 3138
6. T.A. Fehniger, and M.A. Caligiuri Interleukin 15: biology and relevance to human disease Blood 97 2001 14 32
7. W.E. Carson, K.G. Giri, M.J. Lindemann, M.L. Linett, M. Ahdieh, R. Paxton, D. Anderson, J. Eisenmann, K. Grabsten, and M.A. Calgiuri Interleukin IL15 is a novel cytokine that activates human natural killer cells via components of the IL2 receptor J. Exp. Med. 180 1994 1395 1403
8. M.J. Brunda, L. Luisto, R.R. Warrier, R.B. Wright, B.R. Hubbard, M. Murphy, S.F. Wolf, and M.K. Gately Antitumor and antimetastatic activity of interleukin 12 against murine tumors J. Exp. Med. 178 1993 1223 1230
9. M.J. Smyth, M. Taniguchi, and S.E. Street The antitumor activity of IL12: mechanisms of innate immunity that are dose and model dependent J. Immunol. 165 2000 2665 2670
10. C.N. Baxevanis, A.D. Gritzapis, and M. Papamichail In vivo antitumor activity of NKT cells activated by the combination of IL12 and IL18 J. Immunol. 171 2003 2953 2959
11. C.A. Dinarello, D. Novick, A.J. Puren, G. Fantuzzi, L. Shapiro, H. Muhl, D.Y. Yoon, L.L. Reznikov, S.H. Kim, and M. Rubinstein Overview of interleukin 18: more than an interferon γinducing factor J. Leukoc. Biol. 63 1998 658 664
12. Q. Wang, H. Yu, D. Ju, L. He, J.P. Pan, D.J. Xia, L.H. Zhang, and X. Cao Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma Gene Ther. 8 2001 542 550
13. K. Takeda, H. Tsutsui, T. Yoshimoto, O. Adachi, N. Yoshida, T. Kishimoto, H. Okamura, K. Nakanishi, and S. Akira Defective NK cell activity and Th1 response in IL18-deficient mice Immunity 8 1998 383 390
14. S.M. Singh, H. Yanagawa, M. Hanibuchi, T. Miki, H. Okamura, and S. Sone Augmentation by interleukin-18 of MHC-nonrestricted killer activity of human peripheral blood mononuclear cells in response to interleukin-12 Inter. J. Immunopharm. 22 2000 35 43
15. M. Strengell, S. Matikainen, J. Siren, A. Lehtonen, D. Foster, I. Julkunen, and T. Sareneva IL-21 in synergy with IL-15 or IL-18 enhances IFN-γproduction in human NK and T cells J. Immunol. 170 2003 5464 5469
16. A. Paananen, R. Mikkola, T. Sareneva, S. Matikainen, M. Andersson, I. Julkunen, M.S. Salkinoja-Salonen, and T. Timonen Inhibition of human NK cell function by valinomycin, a toxin from Streptomyces griseus in indoor air Infect. Immun. 68 2000 165 169
17. T.A Fehninger, M.H. Shah, M.J. Turner, J.B. VanDeusen, S.P. Whitman, M.A. Cooper, K. Suzuki, M. Wecher, F. Goodsaid, and M.A. Calgiuri Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response J. Immunol. 162 1999 4511 4520
18. Q.H. Nguyen, R.L. Roberts, B.J. Ank, S.J. Lin, E.K. Thomas, and E.R. Stiehm Inteleukin (IL)-15 antibody-dependent cellular cytotoxicity and natural killer activity in neonatal cells Cell Immunol. 185 1998 83 92
19. M.E. Ross, and M.A. Caligiuri Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response Blood 89 1997 910 918
20. S.J. Lin, L.Y. Wang, Y.J. Huang, and M.L. Kuo Effect of interleukin IL-12 and IL15 on apoptosis and proliferation of umbilical cord blood mononuclear cells Bone Marrow Transplant. 28 2001 439 445
21. A.A. Rayner, E.A. Grimm, M.T. Lotze, E.W. Chu, and S.A. Rosenberg Lymphokine activated killer (LAK) cells: analysis of factors relevant to the immunotherapy of human cancer Cancer 55 1985 1327 1333
22. W.E. Carson, R. Parihar, M.J. Lindemann, N. Personeni, J. Dierksheide, N.J. Meropol, J. Baselga, and M.A. Calgiuri Inteleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells Eur. J. Immunol. 31 2001 3016 3025
23. I. Schmid, W.J. Krall, C.H. Uittenbogaart, J. Braun, and J.V. Giorgi Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry Cytometry 13 1992 204 208
24. W.E. Carson, T.A. Fehniger, S. Haldar, K. Eckhert, M.J. Lindemann, C.-F. Lai, C.M. Crose, H. Baumann, and M.A. Caligiuri A potential role for interleukin-15 in the regulation of human natural killer cell survival J. Clin. Invest. 99 1997 937 943
25. S. Bulfone-Paus, D. Ungureanu, T. Pohl, G. Lindner, R. Paus, R. Ruckert, H. Krause, and U. Kunzendorf Interleukin-15 protects from lethal apoptosis in vivo Nat. Med. 3 1997 1124 1128
26. D. Wallach, E.E. Varfolomeev, N.L. Malinin, Y.V. Goltsev, A.V. Kovalenko, and M.P. Boldin Tumor necrosis factor and Fas signaling mechanisms Annu. Rev. Immunol. 17 1999 331 367
27. Y. Tokuda, Y. Ohnishi, K. Shimamura, M. Iwasawa, M. Yoshimura, Y. Ueyama, N. Tamaoki, T. Tajima, and T. Mitomi In vitro and in vivo anti-tumor of a humanized monoclonal antibody against c-erbB-2 product Br. J. Cancer 73 1996 1362 1365
28. R.A. Clynes, T.L. Towers, L.G. Presta, and J.V. Ravetch Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets Nat. Med. 6 2000 443 446
29. T.A. Waldmann Immunotherapy: past, present and future Nat. Med. 9 2003 269 277
30. P.A. Aldertsson, P.H. Basse, M. Hokland, R.H. Golddarb, J.F. Nagelkerke, U. Nannmark, and P.J.K. Kuppen NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity Trends Immunol. 24 2003 603 609
31. E. Chang, and S.A. Rosenberg Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy J. Immunother. 24 2001 88 90
32. T.A. Fehniger, M.A. Cooper, and M.A. Caligiuri Inteleukin-2 and interleukin-15: immunotherapy for cancer Cytokine Growth Factor Rev. 13 2002 169 183